VIANEX and Johnson & Johnson renew their partnership
Johnson & Johnson and VIANEX Group renew and expand their strategic partnership with the aim of further enhancing Greek patients’ access to innovative therapies of high clinical value.
The new agreement is developed on two directions:
- The extension of the existing distribution and promotion agreement for Paliperidone and Rabeprazole formulations until the end of 2028.
- The conclusion of a new agreement for the distribution and promotion of J&J’s Pulmonary Arterial Hypertension portfolio in the Greek market.
Daniel Paksy, Managing Director of Johnson & Johnson Innovative Medicine for Greece and Romania, stated: “The renewal and further expansion of our collaboration with the Greek pharmaceutical company VIANEX reflects our commitment to ensuring substantial and reliable access for Greek patients to innovative therapies of high clinical value. Through partnerships based on trust, high quality and know-how in the products and services provided, we work to ensure that scientific progress is translated into tangible benefits for patients and society as a whole.”
On his part, Dimitris Giannakopoulos, President and CEO of VIANEX S.A., noted: “At VIANEX Group, we are proud to expand our collaboration with Johnson & Johnson Innovative Medicine. This development reinforces our commitment to offering innovative, high-value solutions and confirms our position at the top of the pharmaceutical industry. This expansion reflects our commitment to developing strategic partnerships that enhance value for all involved and contribute substantially to the health of Greek patients.”
